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Colony stimulating factors (CSF) 1 are a class of hemopoietic regulatory glyco- 
proteins required for survival, proliferation, and differentiation of hemopoietic 
stem and progenitor cells in vitro, and probably in vivo (1, 2). Many efforts have 
been  undertaken  to characterize  the biochemical and  biological properties of 
these factors.  In the routine system, CSF stimulating the growth of progenitor 
cells of neutrophil granulocytes (G-CSF), of macrophages (M-CSF or CSF-1), of 
macrophages  and  granulocytes  (GM-CSF),  and  of mixed  colonies  containing 
erythrocytes,  granulocytes,  macrophages,  and  megakaryocytes  (multi-CSF  or 
interleukin  3  [IL-3])  have  been  purified  to  homogeneity (3-6).  It  is  not  yet 
known  whether  these  four  murine  CSF  account  for  all  biological  activities 
originally ascribed to a greater number of specialized colony-stimulating activities 
that had been defined operationally on the basis of colony morphology. Through 
the advent of molecular biology, it has become possible to genetically clone some 
of these factors (7, 8). 
Initial attempts to purify human CSF were less successful. Recently however, 
CSF-1, GM-CSF, and erythroid potentiating activity (EPA), a  CSF-like activity, 
have  been  purified  to  homogeneity  (9-12),  and  human  GM-CSF  has  been 
genetically cloned and sequenced (13). 
We have purified to apparent homogeneity a pluripotent hemopoietic colony 
stimulating factor from conditioned media of the human urinary bladder carci- 
noma  cell  line,  5637  (14).  The  purified  molecule,  which  we  have  termed 
pluripotent CSF  (pCSF) or pluripoietin, supports colony formation of normal 
human  bone  marrow  in  vitro  from  muitipotential  (colony  forming  unit  of 
granulocytes/erythrocytes/macrophages/megakaryocytes  [CFU-GEMM])  and 
early erythroid (burst forming unit of erythroid cells [BFU-E]) progenitors, as 
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I Abbreviations  used in this paper:  ANAE, c~-naphthyl actetate esterase; BFU-E, burst-forming unit 
of erythroid cells;  CFU-GM, CFU of granulocyte/macrophage; CM,  conditioned medium; CML, 
chronic myelogenous leukemia; CSF,  colony-stimulating factor;  DF,  differentiating factor;  EPA, 
erythroid  potentiating activity; FBS,  fetal  bovine serum;  fMLP,  N-formyl-L-methionyl-L-leucyl-L- 
phenylalanine; IL-3,  interleukin 3;  LAL,  limulus amebocyte lysate; LFB,  Luxol  Fast Blue;  PBS, 
phosphate-buffered saline; pCSF, human pluripotent colony stimulating factor  (pluripoietin); RP- 
HPLC, reverse-phase high-performance liquid chromatography; SDS-PAGE, sodium dodecylsulfate- 
polyacrylamide gel electrophoresis; TdR, thymidine. 
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well as unipotential and bipotential granulocyte and macrophage progenitor cells 
(CFU-GM).  IL-3, the only murine CSF known to support multipotential colony 
growth, has a variety of biological activities (reviewed in  15,  16) on hemopoietic 
progenitor cells,  mast cells, and  their precursors,  and possibly on lymphocytes 
(17).  We  wished  to  study  additional  biological  effects  of  purified  pCSF  on 
progenitors and mature cells of normal and malignant hemopoiesis in mouse and 
man. 
Materials and  Methods 
Cell Lines.  The human leukemia cell line, KG-1  (passage  21) and KG-la, a line with 
an undifferentiated blast-like appearance, which was spontaneously derived from KG-1 
(18), were generously provided by H. Koeffler, Department of Medicine, University of 
California, Los Angeles. The HL-60 promyelocytic leukemia cell line, originally obtained 
from R.  Galio (National Cancer Institute, Bethesda, MD),  and WEHI-3B (D+) murine 
myelomonocytic cell line were continuously maintained in our laboratory. Cell lines were 
tested for consistency with published characteristics using morphologic, cytochemical, and 
karyotypic analysis (19). The murine I L-3-dependent cell line, FDC-P2 was obtained from 
T. Dexter (Department of Experimental Hematology, Paterson Laboratories, Wilmington, 
Manchester, United Kingdom). 
Separation  of Bone Marrow Cells.  Bone marrow cells from healthy human volunteers, 
who  gave  informed  consent,  were  separated  and  depleted  of adherent  cells  and  T 
lymphocytes, as described (20, 21). Briefly, after density gradient centrifugation on Ficoll- 
Hypaque, and washing, low-density cells were depleted of adherent cells by incubation on 
plastic surfaces in RPMI  1640 supplemented with glutamine, antibiotics, and  10% heat- 
inactivated fetal bovine serum (FBS). Nonadherent cells were recovered by gently rinsing 
the dishes with medium, and were further depleted of T  lymphoctyes by rosetting with 
neuraminidase-treated sheep red blood cells, and by density gradient separation on Ficoll. 
The final cell population contained <2% monocytes, as judged using a-naphthyl acetate 
esterase (ANAE) stain, and <1% T  lymphocytes by E-rosetting. Fresh leukemic marrow 
cells from a patient with newly diagnosed Phi-positive chronic myeloid leukemia (CML) 
in chronic phase were separated by density gradient centrifugation as described above. 
This population of cells contained <5% ANAE-positive cells, and >90% had the morpho- 
logical appearance of myeioid cells and their precursors after Giemsa staining. 
CFU-GM Colony Assay and Pre-CFU Assay.  For CFU-GM assay, low density, nonadher- 
ent, and T  cell-depleted normal human bone marrow cells were cultured in 0.3% agar 
in supplemented McCoy's medium, as described (22). When cultured at concentrations of 
up to  10 "~ cells/ml for 7-14 d  at 37°C in 5% CO2 in air at  100% humidity, no colony 
(aggregates  of >40  cells)  or cluster  (1-40  cells)  formation was  observed without  the 
addition of exogenous sources of CSF.  Therefore, this cell population seemed largely 
deprived of endogenous producers of CSF.  For study of progenitor cells of CFU-GM, 
termed pre-CFU (23), the same cell population was incubated in liquid culture for 5,  7, 
or 9 d before agar culture. Quadruplicate cultures of 2.5 ×  104 cells in 100/zl/well were 
incubated  in  96-well  flat-bottom  tissue  culture  trays  in  Iscove's  modified Dulbecco's 
medium (Gibco Laboratories, Grand Island, NY) supplemented with 30% FBS, 5 ×  10  -5 
M 2-mercaptoethanol, and serial dilutions of purified pluripotent CSF or control medium 
at 37°C in  5% CO2 in air at  100% relative humidity. Contents of each well were then 
resuspended and incorporated into a 1-ml system in supplemented McCoy's, and cultured 
as outlined above for the CFU-GM assay. Because the purpose of this experiment was to 
determine the ability of pCSF to support survival and growth of pre-CFU in liquid culture, 
we used as an external source of CSF for the final culture, in agar-saturating concentrations 
(10%  vol/vol) of human  bladder carcinoma cell line  5637-conditioned medium (CM). 
This CM contains other growth factor(s) in addition to pCSF, and it supported optimal 
colony growth from CFU-GM progenitor cells surviving or generated during suspension 
culture with purified pCSF alone. For morphological studies of colonies, whole agar dishes 1790  ACTIVITIES OF  HUMAN  PLURIPOTENT COLONY-STIMULATING FACTOR 
from CFU-GM cultures were transferred to glass slides and stained for ANAE, Luxol Fast 
Blue (LFB) or Kaplow's myeloperoxidase with Harris' hematoxylin counterstain (21). 
Assay for Leukemia Differentiation Induction.  Titrated  samples of purified pCSF,  or 
dialyzed  reverse-phase high-performance  liquid  chromatography (RP-HPLC)  fractions 
were  tested  for  differentiation  induction  (GM-DF  [differentiating  factor]  activity)  of 
WEHI-3B (D+) or HL-60 leukemia cells in a clonal assay system (24, 25).  Briefly, 3 X l0 s 
cells/ml  WEHI-3B (D+)  or  103  cells/ml  HL-60  cells  were  incubated  in  0.3%  agar  in 
supplemented McCoy's medium containing  12.5%  FBS in 0.2  ml/well in  24-well tissue 
culture trays (Costar, Cambridge, MA) in replicates at 37 °  in  5%  CO2  in air. Cultures 
were scored on day 7 (WEHI-3B) or day 14 (HL-60) for induction of disperse, differen- 
tiated colonies or tight, blast cell colonies. Total cloning efficiency was close to 30% for 
WEHI-3B (D+) and 10% for HL-60 in all assays, and was not changed significantly in the 
presence of pCSF. This assay allows for easy quantitation of GM-DF activity, and closely 
parallels differentiating activity as measured by morphological and functional criteria (26, 
27). Analogous to the definition of units (U) of GM-CSF activity, 50 U of GM-DF activity 
were  arbitrarily  defined  as  inducing  50%  differentiated  colonies.  For  morphological 
analysis of leukemic cell colonies,  whole agar plates from  1-ml cultures  in petri dishes 
were stained as described above. 
Assay for [3H]Thymidine  Uptake.  Leukemic cell  lines  or  bone  marrow cells  from a 
patient  with  leukemia  (see  above)  were  cultured  at  different  cell  concentrations  in 
supplemented RPMI  1640 containing  10% FBS, with varying concentrations of purified 
pCSF or control medium in 96-well flat-bottom plates (3596; Costar) at 37 °C in 5% CO2 
in air. After the indicated periods of time, cultures were pulsed for 4 h with 0.5 #Ci/well 
[3H]thymidine ([3H]TdR) (New England Nuclear, Boston, MA), and the [aH]TdR uptake 
measured as described previously (28). 
Assay for Binding  of Chemotactic Peptide.  Mature  granulocytes  were  obtained  from 
peripheral blood of healthy human volunteers by buoyant density centrifugation. Briefly, 
buffy-coat cells  from  heparinized  peripheral  blood  were  diluted  1:3  with  phosphate 
buffered saline (PBS), layered over a discontinuous gradient of Ficoll-Hypaque of densities 
1.077 and 1.119 (Sigma Chemical Co., St. Louis, MO), and centrifuged at 2,000 rpm for 
40 min at room temperature.  Cells from the lower interphase (1.119)  were harvested, 
washed three times, and adjusted to a  concentration of 10 ~ viable cells per milliliter of 
RPMI  1640 containing 10% FBS. This cell preparation contained >95% polymorphonu- 
clear cells by Giemsa stain. For induction of receptors for N-formyl-L-methionyl-L-leucyl- 
L-phenylalanine (fMLP), cells were incubated at the given concentration in a total volume 
of 1 ml, in the presence or absence of purified pCSF at 37°C for varying periods of time. 
Measurement  of specific  binding  of fMLP  was  performed  as  described,  with  nfinor 
modifications (29).  Shortly, supernatant was removed after centrifugation, and cells were 
incubated with  15  nM  [3H]fMLP (New England  Nuclear) in  150 #1 medium for 3 h at 
4 ° C. Radioactivity associated with cells was determined by harvesting cells onto glass fiber 
disks, washing with cold PBS,  and counting by liquid scintillation spectroscopy. Specific 
binding  was  calculated  as  the  difference  of activity  (cpm)  bound  in  the  absence  and 
presence of 100 #M cold fMLP. 
Biochemical Procedures.  Biochemical  purification  and  separation  of pCSF  was  per- 
formed using sequential ammonium sulfate precipitation, anion-exchange chromatogra- 
phy, gel filtration, and RP-HPLC, as described (14).  For the experiment described here, 
fractions containing pCSF from anion-exchange column and gel filtration were loaded 
onto a uBondapak C18 column in 0.9 M acetic acid/0.2  M pyridine buffer, pH 4.0, with 
20%  1-propanol, and subsequently eluted with a  linear gradient of 20-50%  1-propanol 
in acetic acid/pyridine buffer at a  flow rate of 1 ml/min. Purified pCSF migrated as a 
single band of Mr  18,000  in sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE). Protein concentration of the band was estimated by comparison with serial 
dilutions of known amounts of proteins in SDS-PAGE. 
Assay for Bacterial Endotoxins.  The preparations of purified pluripoietin (pCSF) used 
in  these studies were tested  for endotoxin contamination in  limulus amoebocyte lysate 
(LAL) assays, kindly performed by R. Sholman (New York Blood Center),  or using an PLATZER  ET  AL.  1791 
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FIGURE  1.  Pooled fractions with pluripotent activity eluted from a gel filtration column were 
acidified  and  loaded  onto a  RP-HPLC C  18  column  in  20%  l-propanol  (see  Materials and 
Methods). Bound proteins were eluted with a linear gradient of 20-50%  1-propanol. Fractions 
of 3  ml each were collected and tested for pluripoietin (&) and GM-DF activity on HL-60 (O) 
and WEHI-3B (D+) (O) leukemic cells. 
FDA-approved LAL test kit (Byk Mailinckrodt, Konstanz, Federal Republic of Germany). 
Results obtained  with different batches  of pCSF indicated  endotoxin contents  ranging 
from <1 ng/106 U of pCSF to <1 ng/1.9 X 104 U of pCSF. 
Results 
Pluripoietin  Induces  Differentiation  of Leukemia Cell  Lines.  Pluripotent  CSF 
from CM of human bladder carcinoma cell line 5637 was purified by sequential 
ammonia sulfate precipitation,  anion-exchange  chromatography,  and gel filtra- 
tion, as described  previously  (14).  In  the final purification  step on  RP-HPLC, 
pCSF  measured  as GM-CSF and  GM-DF for both HL-60  and  WEHI-3B  (D+) 
eluted together at a  1-propanol concentration  of 42%  (Fig.  1).  pCSF from this 
fraction  appeared  to be  purified  to homogeneity  (14);  it  migrated  as a  single 
band in silver-stained SDS-PAGE coincident with GM-CSF activity and GM-DF 
on both leukemia cell lines (data not shown). 
An additional peak of GM-DF activity eluted at a lower 1-propanol concentra- 
tion, separate from pCSF (Fig.  1). Fractions from this peak were highly active in 
inducing differentiation of HL-60 cells, but had low activity on WEHI-3B  (D+) 
cells and in the GM-CSF assay  on day 7.  Purification of the material contained 
in this peak, designated pluripoietin-0~, will be published elsewherefl 
HL-60  and  WEHI-3B  (D+)  leukemia  cells  were  differentially  sensitive  to 
differentiation  induction  by  pCSF.  Two  independent  purification  procedures 
resulted  in virtually  identical  specific biological  activities  of 1.25-1.5  ×  108  U 
GM-CSF/mg protein, and in very similar GM-CSF/GM-DF activity ratios (Table 
I). WEHI-3B  (D+) cells were clearly more sensitive to differentiation induction 
2 Gabrilove, J.  L., K. Welte, P. Harris, E. Platzer, L. Lu, R. Mertelsmann,  and M. A. S. Moore. 
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TABLE  I 
Colony-stimulating and Leukemia-differentiating Activity of Purified Pluripoietin 
Purification 
GM-CSF activity  GM-DF activity WEHI- 
3B (D+)  GM-DF activity HL-60 
Specific ac- 
tivity  DF/CSF  (x  10  8 U/mg  U/ml X  10  3  U/ml x  10  3  DF/CSF  U/ml X 
ratio  103  ratio 
protein) 
I  1.5  84  246  2.9  54  0.6 
II  1.25  201  502  2.5  80  0.4 
Purified pluripoietin from  two  independent purifications (1  and  II)  is compared  for its ability to 
support CFU-GM  (GM-CSF activity), and to  induce differentiation in  human HL-60  and murine 
WEHI-3B (D+) leukemia cells (GM-DF activity) in clonal assays, Units (U) of activity are defined in 
Materials and Methods. Due to different amounts of starting material, the concentrations of biological 
activities differ between I and II, but are similar relative to each other. 
by pCSF than was HL-60, which required approximately five times more pCSF 
for comparable effects. 
Morphologically and cytochemical analysis of HL-60 colonies was performed 
using  ANAE  and  LFB  stains  as  markers  of the  monocyte/macrophage and 
eosinophil granulocyte lineage, respectively, with Harris' hematoxylin counters- 
tain for nuclear morphology. In the presence of pCSF we observed an increase 
(of up  to  75%)  in  the percentage of HL-60  colonies containing a  significant 
number (>10%)  of polymorphonuclear cell colonies, as compared to  15-20% 
for control medium, and the appearance of some LFB + cells, as well as an increase 
in intensity of ANAE stain. WEHI-3B (D+) colonies, although positive for ANAE 
when grown in  the absence of pCSF,  stained with higher intensity for ANAE 
when induced with pCSF.  Taken together, these data suggest that pCSF  may 
induce  differentiation of leukemia ceils  towards  granulocytes and/or  macro- 
phages (GM-DF). 
Pluripoietin  Induces  [aH]TdR  Uptake  in  Fresh  Leukemia  Cells  and  in  KG-1 
Leukemia Cell Line.  Light-density bone marrow cells from a previously untreated 
patient with Phi-positive CML were incubated with titrated samples of purified 
pCSF.  A  dose-dependent  increase  in  [SH]TdR  uptake  was  observed  in  the 
presence of pCSF as compared to control medium on day 3 of culture (Table 
II). Similar changes in [3H]TdR uptake were obtained after 5 and 7 d of culture, 
and  in  the  7-d  colony assay  in  semisolid agar  using  the same cells  (data  not 
shown). 
KG-1  leukemia cells with myeloblast to promyelocyte morphology are known 
to be susceptible to growth modulation in vitro by CSF (30). Significant enhance- 
ment of [aH]TdR uptake was seen in KG-1  cells (passage 24) in the presence of 
pCSF  within  24  h  (Table  III).  in  this  particular  experiment, pCSF  could be 
detected at 13 U/ml; yet 25-50 U/ml consistently gave significant enhancement 
of [aH]TdR  uptake.  Passages  later than  45  gradually lost  this  responsiveness, 
giving an increase only ~<25% in [~H]TdR uptake. A somewhat higher increase 
of up to twofold over medium control could be seen with early passages of KG- 
1 after 3  d  of incubation.  [3H]TdR  uptake of KG-1  cells or,  as shown above, 
fresh CML marrow cells may be used as a  fast and sensitive screening assay to PLATZER  ET  AL. 
TABLE  II 
[3H]TdR Uptake by CML Marrow Cells in Response to Pluripoietin 
Treatment  [SH]TdR uptake  Stimulation 
index 
cpm 
Control medium  2,144  1.0 
1793 
Pluripoietin (U/ml) 
500  17,123  8.0 
250  14,384  6.7 
125  I 1,828  5.5 
63  6,939  3.2 
31  4,505  2.1 
15  5,356  2.5 
Crude 5637-CM 
500 U/ml  23,912  11.2 
Light-density bone marrow cells from a previously untreated patient with 
Ph' +  CML in chronic phase were cultured at 2 ×  105 cells/200  tzl/well 
with titrated samples of purified pluripoietin, or control medium for 3 d. 
Results are expressed  as mean cpm from  triplicate  cultures.  Stimulation 
index is the ratio of cpm from cultures in the presence of pCSF to cpm 
from control cultures. 
TABLE III 
[SH]TdR Uptake by Human Leukemic Cell Line KG-I 
Treatment  [3H]TdR uptake 
cpm  % 
Control medium  3,660 _+ 108  100 
Pluripoietin (U/ml) 
200  5,366 _+ 176  147 
100  5,245 + 4  143 
50  4,935 ___ 180  135 
25  4,553 __. 178  130 
13  4,553 _.+ 6  124 
6  4,363 + 493  119 
KG-1 cells of passage 24 were incubated at t 5,000 cells/well for 24 h with 
titrated samples of purified pluripoietin, or control medium. Results are 
expressed  as  mean cpm  +  SD  for  triplicate  cultures.  Differences  are 
significant on a 5% level at ~13 U/ml, using a two-tailed Student's t-test. 
monitor  purification of pCSF  and  pluripoietin-a. KG-la,  an  undifferentiated 
variant of KG-1, did  not respond to  pCSF by increased [3H]TdR uptake (data 
not shown). 
In  14-d semisolid agar culture, pCSF enhanced colony formation from KG-1 
ceils (passage 50) by 1.7-3.1-fold, at a  cloning efficiency of 1.5-3.2% at 3  ×  103 
cells/ml  (data  not  shown).  Also,  a  pronounced  increase  in  colony  size  was 
observed. 
Pluripoietin Promotes Survival and Proliferation of Normal Hemopoietic Progenitor 
Cells and  Their Precursors.  In  the  CFU-GM  assay  in  semisolid agar,  purified 1794  ACTIVITIES  OF  HUMAN  PLURIPOTENT  COLONY-STIMULATING  FACTOR 
TABLE  IV 
Activity of Pluripoietin on Pre-CFU 
Exp. 1  Exp. 2  Exp. 3 
Pluripoietin concentra-  (7 d in suspen-  (7 d in suspen- 
tion  5 d in suspen-  9 d in suspen- 
sion culture)  sion culture)  sion culture  sion culture 
U/ml 
1,000  260±  18  80±- 11  128+20  320±32 
500  307 ±  20  156 +  16  NT  NT 
100  200 ±  18  116 ±  29  292 ±  17  122 +  21 
10  145 ±  15  48 +  11  203 ±  13  136 ±  18 
Control medium  104 ±  20  32 +  9  105 ±  21  81  _  13 
Light-density, adherent cell and T  lymphocyte-depleted normal human bone marrow cells were 
incubated in suspension culture with titrated samples of purified pluripoietin or control medium. 
After indicated periods of time, cells were resuspended and plated in semisolid agar culture with 
saturating concentrations of exogenous CSF (5637-CM), and colonies were counted 7 d later. Results 
are expressed as mean +  SD colonies from quadruplicates per 10 s cells input on day 0 of suspension 
culture. The numbers of colony-forming progenitors input at that time were 204 +  10,  104 ±  4, 88 
±  12, for Exp. 1, 2, and 3, respectively. 
pCSF stimulates colony formation from normal human bone marrow cells. On 
day 7 of culture, >90% of colonies observed were granulocytic, whereas on day 
14,  granulocytic, monocytic, and  mixed granulocytic/monocytic colonies and 
some eosinophilic clusters were seen (data not shown). When used at a concen- 
tration  of 500  U/ml,  pCSF  also  supported  human  BFU-E  and  CFU-GEMM 
colony formation in methylcellulose in the presence of erythropoietin (14). CFU- 
GEMM possess limited self-renewal and high proliferative capacity in vitro, and 
are probably closely related to hemopoietic stem cells (31, 32). CFU-GM on the 
other hand, are committed to proliferate and differentiate along the GM path- 
way, having minimal self-renewal capacity in vitro. Since pCSF works on both 
early and late progenitor cells, we wished to study its activity on survival and 
generation of CFU-GM  from pre-CFU progenitor cells, which are thought to 
comprise earlier cell types in the hierarchy of hematopoietic stem and progenitor 
cells (23).  Pre-CFU are detected by suspension culture in the presence of CSF 
before assay  for  clonai  growth  in  semisolid  agar  culture.  This  procedure  is 
assumed for proliferation and terminal differentiation in liquid culture of com- 
mitted  CFU-GM  progenitors  present  at  initiation  of culture,  which  cannot 
subsequently be  detected in  agar  culture.  Light-density normal  human  bone 
marrow cells, devoid of endogenous producers of CSF by depletion of adherent 
cells  and  T  lymphocytes,  were  cultured  at  low  cell  densities.  As  expected, 
extensive proliferation and differentiation of target cells were observed during 
suspension  culture in  the presence of pCSF  (data  not shown).  Purified pCSF 
supported the survival, expansion and differentiation of early progenitor cells 
(pre-CFU) to committed CFU-GM  progenitors, which then gave rise to day 7 
colonies in semisolid agar culture (Table IV). In two of three experiments, the 
number of CFU-GM progenitors present in liquid culture declined in the absence 
of pCSF  (Table  IV),  consistent with  the requirement for CSF  for survival  of 
progenitor cells (33). In one additional experiment (data not shown), we observed 
an  increase  in  CFU-GM  after  7  day  suspension  culture  in  the  absence  of PLATZER  ET  AL. 
TABLE V 
Induction of Chemotactic Peptide Binding in Mature Granulocytes by 
Pluripoietin 
Treatment time  [3H]fMLP specific binding 
min  cpm 
0  1,040 ±  140 
10  1,580 ±  210 
20  1,900 ±  420 
30  3,740 ±  1,250 
Highly  enriched  polymorphonuclear  cells  from  peripheral  blood  of a 
normal donor were preincubated with 5,000 U/ml of purified pluripoietin 
at 37 °C for the periods of time indicated, before assay for fMLP binding 
at 4°C. Specific binding is calculated as the difference of [SH]fMLP binding 
in the presence or absence of excess cold fMLP. Pooled results from two 
independent experiments are presented as mean cpm _  SE. 
1795 
exogenous CSF.  Cells  from this  particular  volunteer on  several occasions ex- 
hibited a very high cloning efficiency in agar cultures, despite the absence of any 
recognizable pathophysiologic situation. In this experiment, pCSF enhanced the 
number of CFU-GM surviving or generated in liquid culture. 
In all experiments, >90% of colonies grown in the final agar culture contained 
granulocytes and their precursors. 
Pluripoietin Shows Little Cross-species Activity on Murine Cells Other Than WEHI- 
3B (D+).  When normal murine bone marrow cells from CBA/Hn mice were 
plated in semisolid agar, pCSF supported purely granuiocytic colony formation 
on  day 7  at  low  cloning efficiency. Saturating amounts (500  U/ml) of pCSF 
supported growth of 8.5  +  0.7  colonies and  10.5  _  0.7 clusters per 7.5  ×  104 
cells plated, as compared to 112 -+ 9 colonies and 143 +  3 clusters in the presence 
of  10%  WEHI-3B  as  an  optimal  exogenous source of CSF.  However,  pCSF 
supported significantly more colony formation than control medium (0.3 +  0.3 
colonies, 12 +  8 clusters; p <  0.01, two-tailed Student's t-test). Colonies consisted 
of very small cells of granulocytic morphology by hematoxylin stain. 
The  murine  factor-dependent hemopoietic cell  line  FDC-P2  proved  unre- 
sponsive to pCSF when assayed for [3H]TdR uptake after 24,  48, and 72 h  in 
culture. A  murine long-term mast cell line showed low levels of responsiveness 
to pCSF (Y.  Yung,  Memorial Sloan-Kettering Cancer Center, unpublished ob- 
servation). 
Pluripoietin  Enhances  Chemotactic  Peptide  Binding  on  Mature  Granulocytes. 
Although CSF  are defined mainly by their activity on  colony-forming hemo- 
poietic  progenitor  cells,  evidence  is  accumulating  that  CSF  have  important 
biological effects on mature cells of the hemopoietic system like granulocytes, 
macrophages, or mast cells (reviewed in  16). When pCSF was tested for activity 
on mature cells, 5,000  U/ml of pCSF acted within minutes to enhance specific 
binding  of the  chemotactic peptide  fMLP  to  highly enriched populations  of 
mature  human  peripheral  blood  neutrophil  granulocytes  (Table  V).  Similar 
though less pronounced effects were observed at concentrations of pCSF as low 
as 300 U/ml (data not shown). No significant change in fMLP binding was seen 1796  ACTIVITIES  OF  HUMAN  PLURIPOTENT  COLONY-STIMULATING  FACTOR 
for 30 min in the absence of pCSF. Although these experiments do not discrim: 
inate between increased numbers of receptors or increased affinity for fMLP, 
the effect of pCSF on specific fMLP binding was highly significant (p <  0.01  at 
30  min  in  each  experimeaat of Table  V,  two-tailed  Student's  t-test).  Control 
experiments excluded bacterial endotoxin contamination of pCSF preparations 
as  a  possible  cause  of enhanced binding  of chemotactic peptide.  Under our 
experimental conditions,  up  to  1 ng/ml  of endotoxin (Novopyrexal; Hermal- 
Chemie, Hamburg, Federal Republic of Germany) did not change fMLP binding 
to mature granulocytes. In contrast,  1,000  U/ml of pCSF, containing <0.5 ng/ 
ml endotoxin increased fMLP binding more than twofold over that induced by 
100 ng/ml endotoxin (data not shown). 
Discussion 
The present era of cytokine research is characterized by an increasing number 
of factors becoming available  in  purified  natural  or  recombinant form.  New 
studies have to compare these well-defined factors and evaluate them for activities 
originally ascribed to a plethora of cytokines that were operationally defined by 
the assays used for their study. 
We  report  here  on  some  biological  activities  of natural  pluripotent  CSF, 
purified to homogeneity from CM  of the human bladder carcinoma cell line, 
5637. As reported earlier (14), pluripoietin (pCSF) supports colony formation in 
the presence of erythropoietin from  normal  human  multipotentiai  and  early 
erythroid progenitors.  This  feature distinguishes pluripoietin  from the  other 
purified human growth factors, GM-CSF, CSF-1, and EPA, all of which lack this 
activity partially or completely. Also, pluripoietin differs from human GM-CSF 
by amino acid sequence analysis (our unpublished observation).  In contrast to 
pluripoietin, CSF:I  appears to be a dimeric molecule (3,  10), and eight neutral- 
izing  rabbit  antisera  to  CSF-1  (anti-L  cell  CSF,  generously provided  by  R. 
Shadduck, Department of Medicine, Montefiore Hospital,  Pittsburgh,  PA) did 
not neutralize pluripoietin in the CFU-GM assay (our unpublished observation). 
The only murine.CSF  known  to  support  multipotential  colony growth,  IL-3, 
initially appeared to be a possible murine homologue to pluripoietin. However, 
as will be discussed below, IL-3 lacks the GM-DF activity of pluripoietin. 
Experiments reported here suggest that pluripoietin acts on immature progen- 
itor cells supporting their survival, proliferation, and/or differentiation to com- 
mitted CFU-GM progenitors in suspension culture. This activity of pluripoietin 
seems to be similar to a granulocyte-promoting activity, 6-GPA, partially purified 
from human placental CM (34).  No such experiments were reported on IL-3, 
but it seems to have a similar effect on murine stem cells in vitro before bone 
marrow  transplantation  (35,  36).  Murine  GM-CSF  was  reported  to  support 
survival in vitro and initial proliferative of multipotential and erythroid progen- 
itors (37);  similarly, murine G-CSF sustains survival and initial proliferation of 
CFU-GM and some muhipotential progenitors in fetal liver (38).  In contrast to 
pluripoietin, neither murine GM-CSF nor G-CSF are able to sustain continued 
proliferation of these progenitors resulting in multipotential colony formation. 
Like most other CSF, pluripoietin appears to be acting directly on the progen- 
itor cell level, since depletion from the target cell population of CSF-producing PLATZER  ET  AL.  1797 
adherent cells and T  lymphocytes did not abolish colony formation. Yet pluri- 
poietin also acts on mature hemopoietic cells by enhancing specific binding of 
the chemotactic peptide fMLP to mature normal granulocytes. This is intrigu- 
ingly similar to a report (39) that preincubation of polymorphonuclear cells with 
either purified  natural  or recombinant human  GM-CSF  increases superoxide 
anion  production  in  response  to  fMLP.  There  are  no  published  reports  on 
activities of IL-3  on mature granulocytes, but IL-3  is known to act on murine 
mast  cells,  inducing  histamine  synthesis  (40)  and  polychondroitin  E  sulfate 
production (41). Other human and murine CSF are thought to induce in mature 
cells effector functions like antibody-dependent cellular cytotoxicity, plasmino- 
gen activator production,  tumoricidal and  microbicidal activities (reviewed in 
16).  As  previously  reported  (42),  however  neither  purified  pluripoietin  nor 
purified human CSF-1  enhanced H202  production by mature macrophages in 
an assay system that optimally detected ~'-interferon-induced macrophage acti- 
vation (42). 
A major distinctive feature of pluripoietin is its ability to induce differentiation 
of the human and murine leukemia cell lines  HL-60  and WEHI-3B  (D+).  In 
contrast, IL-3 lacks GM-DF activity (16). Murine G-CSF is known to be a potent 
inducer of leukemic cell differentiation by its ability to  induce of phenotypic 
maturation (26, 27) and clonal extinction (24) in WEHI-3B (D+) cells. Purified 
murine GM-CSF, a less potent inducer of leukemia differentiation, has failed to 
completely suppress the progressive proliferation of WEHI-3B (D+) cells since, 
on serial recloning, leukemic cells maintained in the presence of CSF continued 
to generate cells capable of forming undifferentiated colonies (43). 
In this context, important practical and theoretical implications arise from the 
finding that pluripoietin may have the potential to inhibit leukemic cell growth 
by inducing terminal differentiation and at the same time sustain normal hema- 
topoiesis and activate effector functions in mature cells. A human CSF (urinary 
CSF) has been used already in clinical trials (44).  In leukemia, careful consider- 
ation will have to be given to the possibility of promoting leukemic cell growth 
in  vivo.  In  vitro,  KG-1  leukemia cell line  and CML  bone  marrow cells were 
stimulated by purified pluripoietin to increased proliferation in suspension and 
agar culture.  Possibly, clonal assays, including study of secondary plating effi- 
ciency (PE-2) in vitro, may provide a means of weighing the combined effect of 
proliferation  and  differentiation-inducing stimuli.  Studies  are  under  way  to 
determine how many leukemias will be susceptible to the differentiation-inducing 
potential of pluripoietin. 
Recently,  2 we have succeeded in highly purifying a  second CSF from 5637, 
which we termed pluripoietin-e~. Although this CSF also supports multipotential 
and erythroid colony formation, it is distinguished from pluripoietin by biochem- 
ical characteristics and colony morphology in agar. Pluripoietin and pluripoietin- 
o~ act synergistically on normal human bone marrow in terms of colony numbers 
and size (our unpublished observation). Unlike pluripoietin, however, pluripoie- 
tin-~ is not active on murine bone marrow or WEHI-3B (D+) cells. 
Recently, others  (45)  reported  studies  on  CSF  from  5637-CM.  They also 
observed at least two factors in 5637-CM. Although they have not purified these 
factors, there are some interesting data suggesting that pluripoietin could be a 1798  ACTIVITIES  OF  HUMAN  PLURIPOTENT  COLONY-STIMULATING  FACTOR 
human homologue to murine G-CSF. Evidence was derived from binding/com- 
petition  studies  of purified  murine  G-CSF to  human  and  murine  normal  and 
leukemic  cells.  5637-CM  fractionated  on  phenyl-Sepharose  column  separated 
into two peaks of CSF activity, designated CSF-a and CSF-/3, in analogy to earlier 
work (46) on mouse and human CSF. No evidence was provided that separation 
of the two factors was complete or that  activities ascribed to CSF-/3 are due to 
only one factor. Purified murine G-CSF and fractions containing human CSF-/3 
competed for receptors on human  leukemic promyelocytes and  murine  myeio- 
monocytic  leukemia  cells.  Also,  murine  G-CSF and  human  CSF-/3  both  were 
potent  inducers  of differentiation  of WEHI-3B  (D+),  and  supported  murine 
normal bone marrow colony formation with a cloning efficiency and morphology 
similar to that supported by pluripoietin. Therefore, murine G-CSF and partially 
purified  human  CSF-/3  show  some  intriguing  similarities  to  pluripoietin.  As 
discussed above however, published data (38) indicate that murine G-CSF, unlike 
pluripoietin, does not support the growth of muitipotential colonies and BFU-E. 
Others (47) have found activities supporting the growth of human multipotential 
progenitor cells in  5637-CM as well, however, no biochemical characterization 
of these  activities  was  reported.  Clarification  of this  point  will  have  to  await 
purification of CSF-/3 and/or sequence data on murine G-CSF. 
Another group (48, 49) reported purification of a factor from 5637-CM, using 
as an assay the induction of receptors for purified murine CSF-1 on murine bone 
marrow  cells.  Based  on  these  studies,  a  factor  designated  hemopoietin-1  was 
described in 5637-CM that induced CSF-1  receptors in bone marrow cells from 
5-fluorouracil (5-FU)-treated mice within 3-5 d in culture. Since 5-FU treatment 
depletes  CFU-GM  progenitor  cells and  CSF-l-responsive  cells,  hemopoietin-1 
was assumed to work on earlier progenitor cells. Purified hemopoietin-1  had no 
detectable murine  colony-stimulating activity by itself,  but it appeared  to be a 
multilineage hemopoietic growth factor capable of synergizing with a CSF other 
than CSF-I to support murine multipotential colony growth (49). Because human 
pluripoietin,  in  contrast  to  pluripoietin-a  (our  unpublished  data),  has  some 
detectable  murine  CSF  activity,  and  because  of  biochemical  characteristics, 
hemopoietin-1  appears to be similar to pluripoietin-a rather than pluripoietin. 
It remains for future studies to resolve how many different molecular species 
of CSF there are.  Sequence data available to date indicate no significant degree 
of inter- or intraspecies homology for human and murine CSF. The availability 
of purified  and  cloned  growth  factors  for biological studies  is one step in  the 
elucidation of the complex mechanisms involved in regulation of hemopoiesis. 
Summary 
We studied the biological effects of pluripoietin,  a  human pluripotent  hemo- 
poietic colony-stimulating factor (CSF) purified from the 5637 bladder carcinoma 
cell  line.  We found that  this  human  CSF appears  to be a  unique  hemopoietic 
growth  factor,  differing  from  interleukin  3  (IL-3)  by  virtue  of its  leukemia 
differentiating  activity in  mouse and  man,  and  from  mouse granulocyte  CSF, 
which does have differentiation-inducing  activity, but lacks pluripoietic activity. 
In  addition,  differences  from  IL-3  were  observed  in  cross-species activity  on 
normal and leukemic cells. PLATZER  ET  AL. 
Wethank M. Sullivan and L. Barnett ~rtheirexcellenttechnicalassistance. 
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